KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Cost of Revenue (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Cost of Revenue data on record, last reported at $40.3 million in Q4 2025.

  • For Q4 2025, Cost of Revenue rose 1.04% year-over-year to $40.3 million; the TTM value through Dec 2025 reached $149.7 million, down 12.13%, while the annual FY2025 figure was $149.7 million, 12.13% down from the prior year.
  • Cost of Revenue reached $40.3 million in Q4 2025 per PCRX's latest filing, up from $34.3 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $61.9 million in Q4 2022 and bottomed at $31.3 million in Q1 2021.
  • Average Cost of Revenue over 5 years is $42.2 million, with a median of $40.1 million recorded in 2024.
  • Peak YoY movement for Cost of Revenue: soared 58.73% in 2022, then fell 27.65% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $39.0 million in 2021, then surged by 58.73% to $61.9 million in 2022, then fell by 22.97% to $47.7 million in 2023, then fell by 16.37% to $39.9 million in 2024, then rose by 1.04% to $40.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $40.3 million in Q4 2025, $34.3 million in Q3 2025, and $40.9 million in Q2 2025.